Cargando…

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases

Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rau, Daniela, Lang, Michael, Harth, Andreas, Naumann, Markus, Weber, Frank, Tumani, Hayrettin, Bayas, Antonios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519865/ https://www.ncbi.nlm.nih.gov/pubmed/26132570 http://dx.doi.org/10.3390/ijms160714669

Ejemplares similares

Alemtuzumab-associated diffuse alveolar damage – a case report
por: Bayas, Antonios, et al.
Publicado: (2020)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Two case reports of acquired haemophilia A as complications of alemtuzumab treatment for multiple sclerosis
por: Gounder, Kuhilan, et al.
Publicado: (2021)

The TRACK-MS Test Battery: A Very Brief Tool to Track Multiple Sclerosis-Related Cognitive Impairment
por: Taranu, Daniela, et al.
Publicado: (2022)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
por: Abdelhak, Ahmed, et al.
Publicado: (2015)

Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report
por: Rapp, Daniel, et al.
Publicado: (2020)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Listeria Monocytogenes Septicemia and Meningitis Caused by Listeria Enteritis Complicating Ulcerative Colitis
por: Inoue, Takahiro, et al.
Publicado: (2017)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Cryptococcus gattii Meningitis Complicated by Listeria monocytogenes Infection
por: Deiss, Robert G., et al.
Publicado: (2016)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
por: Li, Z., et al.
Publicado: (2018)

A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
por: Aouad, Patrick, et al.
Publicado: (2018)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis
por: Hu, Hannah, et al.
Publicado: (2020)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
por: Rauma, Ilkka, et al.
Publicado: (2021)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
por: Pastor-Quirós, Luis J., et al.
Publicado: (2021)

ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pmtrshfumorst2s5nmfhpigi7n